InVentiv pushes into Japan again, offering consulting this time

InVentiv pushes into Japan again, offering consulting this time

CRO inVentiv Health subsidiary Campbell Alliance has launched its consulting business in Japan and will open an office in Tokyo nearly a year after inVentiv made its initial push into the country.

James Forte, VP of marketing at Campbell, told Outsourcing-Pharma.com, “Our initial focus in Japan will be on providing services in the areas of market assessment, opportunity identification, pricing and market access, market entry and go-to-market strategy, product launch, commercial excellence, and in- and out-licensing.”

Campbell expects there will be regional variations in Japan as the company attempts to offer services it currently offers in the US and Europe. 

For example, from a pricing and market access standpoint, commercial implications of the Affordable Care Act are a timely topic in the US, while in Japan, communicating a product’s value proposition for coverage on the National Health Insurance system in Japan is critical,” Forte said. 

As far as the expansion, Forte noted that there are no plans to relocate staff from the US or Europe to Japan. 

Many of our projects are global in nature, so our team is accustomed to collaborating across borders under our current infrastructure.  For other projects, working in Japan requires expertise and knowledge of the Japanese market.  An area of strength for us in that regard is our ability to collaborate with our inVentiv Health colleagues (our parent company) who have been on-the-ground in Japan for several years,” he added.

The launch of the new consulting business comes just a year after inVentiv announced a partnership with one of Japan’s largest CROs – Bell Medical Solutions. It also follows moves by other CROs looking to nab a portion of the growing trials sector in Japan.

The office, which will be led by Pawel Komender, will operate as inVentiv Health Consulting.

Related News

InVentiv pushes into Japan again, offering consulting this time

InVentiv pushes into Japan again, offering consulting this time

CRO industry growing in Japan, says report

Japanese pharma using more CROs as large-scale development picks up

(Picture: Flickr/Richard Garside)

Crown and SNBL partner for challenging Japanese CRO market

Lupin and Yoshindo form JV to take on biosimilar market in Japan

Lupin launches JV with Yoshindo to develop biosimilars for Japan

Aprecia selects InVentiv to commercialize its 3-D printing tech

Aprecia selects InVentiv to commercialize its 3-D printing tech platform

The partnership will focus on developing and adopting global standards and performance metrics for clinical trials

ACRES, inVentiv partner to help develop global trial standards

Enrollment in study increases drastically following inVentiv dismissal

Enrollment in Phase III study increases drastically following inVentiv dismissal

Biotech CEL-SCI claims levels of enrolment in Ph III trial dropped after inVentiv acquired CRO Pharmanet

inVentiv: $50m breach of contract claim 'meritless' as trial looms

Tokyo, Japan - will see more multiregional trials in 2015 says Tufts and PPD

Japan to be hot destination for trials in 2015 say experts, despite drop in MRCTs last year

Fresh biotech cash is being re-invested into early phase trials, an inVentiv exec told us

inVentiv ups early phase offering with new clinic in Miami

inVentiv expands NIS services to help stem confusion on new EU trials regulation

inVentiv expands NIS services to help stem confusion on new EU trials regulation

Proteomics teams with inVentiv for biosimilar, biologics development

Proteomics teams with inVentiv for biosimilar, biologics development

InVentiv pushes into Japan again, offering consulting this time

InVentiv pushes into Japan again, offering consulting this time

inVentiv and NeuroVive team on cardio, neurological drugs

inVentiv partners with NeuroVive to bring cardio, neurological drugs to market

Related Products

See more related products